Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
Rhea-AI Summary
Atea Pharmaceuticals (Nasdaq: AVIR) reported first quarter 2026 results and clinical progress. Cash, cash equivalents and marketable securities were $256.0 million at March 31, 2026, down from $301.8 million. Net loss was $45.4 million (basic and diluted loss per share $0.57).
Phase 3 HCV trials remain on track, with C-BEYOND topline data expected mid-2026 and C-FORWARD around year-end 2026. Preclinical data support AT-587 as lead HEV candidate, with Phase 1 initiation targeted for mid-2026.
AI-generated analysis. Not financial advice.
Positive
- C-BEYOND Phase 3 HCV trial enrollment >880 patients; topline data mid-2026
- C-FORWARD global Phase 3 HCV trial enrollment completion targeted mid-2026
- Phase 2 BEM/RZR 8-week regimen achieved 98% SVR12 per-protocol
- Phase 2 BEM/RZR 8-week regimen achieved 95% SVR12 efficacy-evaluable
- HCV regimen shows low risk of drug–drug interactions in recent studies
- AT-587 selected as lead HEV candidate; Phase 1 planned mid-2026
- AT-587 and AT-2490 30–150x more potent vs HEV than sofosbuvir/ribavirin in vitro
- First quarter 2026 R&D increase linked to HCV Phase 3 and HEV development
- General and administrative expenses fell to $6.9M from $9.5M year prior
- Cash, cash equivalents and marketable securities totaled $256.0M at March 31, 2026
Negative
- Cash, cash equivalents and marketable securities declined from $301.8M to $256.0M
- Working capital decreased from $271.2M to $229.8M quarter-over-quarter
- Net loss widened to $45.4M from $34.3M year-over-year
- Loss per share increased to $0.57 from $0.40 year-over-year
- Research and development expenses rose to $41.1M from $29.6M
- Interest income and other, net, fell to $2.6M from $5.0M
- Total stockholders’ equity declined from $275.4M to $233.7M
News Market Reaction – AVIR
On the day this news was published, AVIR declined 16.91%, reflecting a significant negative market reaction. Argus tracked a trough of -13.2% from its starting point during tracking. Our momentum scanner triggered 23 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $90M from the company's valuation, bringing the market cap to $440.15M at that time. Trading volume was very high at 3.4x the daily average, suggesting heavy selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
AVIR was down 0.37% while several biotech peers in the same industry (e.g., CADL +3.94%, OMER +1.56%, IVVD +1.34%) traded higher. Only one peer (TNXP) appeared on the momentum scanner, moving up, indicating stock-specific dynamics rather than a broad sector move.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 05 | Q4/FY25 earnings | Positive | +11.1% | Reported Q4/FY25 results, solid cash of $301.8M, and Phase 3 HCV progress. |
| Nov 12 | Q3 2025 earnings | Neutral | -12.6% | Q3 2025 update with advancing HCV Phase 3 program and new HEV effort. |
| Aug 07 | Q2 2025 earnings | Negative | -2.3% | Q2 2025 loss, lower cash of $379.7M, and noted strategic review. |
| May 12 | Q1 2025 earnings | Negative | -11.2% | Q1 2025 loss, cash decline, workforce reduction, and cost-saving measures. |
| Mar 06 | FY2024 earnings | Neutral | -0.3% | FY2024 results with planned Phase 3 start and higher R&D spending. |
Earnings-related updates have produced mixed but generally cautious reactions, with an average move of -3.05% across the last five earnings events, despite steady progress in the HCV and HEV programs.
Over the past several earnings cycles, Atea has consistently highlighted advancement of its bemnifosbuvir/ruzasvir HCV regimen from End-of-Phase 2 through global Phase 3, and more recently the transition of AT-587 for HEV toward first-in-human studies. Cash and marketable securities have trended lower from $454.7M in FY 2024 to $301.8M at 12/31/2025, reflecting ongoing R&D investment, workforce reductions, and completion of a $25M share repurchase.
Historical Comparison
Across the last five earnings reports, AVIR’s average next-day move was -3.05%, as investors balanced advancing HCV/HEV programs against steadily declining cash balances.
Earnings updates have tracked Atea’s shift from Phase 2 into global Phase 3 trials for HCV, while cash reserves declined from $454.7M in FY 2024 to $301.8M by year-end 2025, and the HEV candidate AT‑587 moved from IND-enabling work toward planned Phase 1 initiation.
Market Pulse Summary
The stock dropped -16.9% in the session following this news. A negative reaction despite detailed progress updates would fit prior earnings patterns, where the average move was -3.05% as investors focused on cash burn and losses. Q1 2026 cash and securities fell to $256.0M, and net loss increased to $45.4M. Even with strong HCV Phase 2 SVR12 rates and approaching Phase 3 readouts, prolonged development timelines and higher R&D spending can weigh on sentiment.
Key Terms
fixed-dose combination medical
nucleotide analog polymerase inhibitor medical
ns5a inhibitor medical
sustained virologic response (SVR12) medical
lower limit of quantitation (LLOQ) medical
modified intent-to-treat medical
per-protocol medical
proton pump inhibitors medical
AI-generated analysis. Not financial advice.
C-BEYOND Phase 3 North American Trial for Treatment of Hepatitis C Virus (HCV) Remains on Track with Topline Results Expected Mid-2026
C-FORWARD Phase 3 Trial Outside North America for Treatment of HCV on Track to Complete Enrollment Mid-2026; Topline Results Expected Around Year-End 2026
Encouraging Preclinical Data Support AT-587 as a Potential First-in-Class Therapy for Hepatitis E Virus (HEV); Phase 1 Initiation Expected Mid-2026
Company Holding Conference Call Today at 4:30 pm ET
BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.
“With two pivotal Phase 3 readouts for our HCV program on the horizon, 2026 will be a catalyst-rich year for Atea,” said Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals. “The data generated to date for the regimen of bemnifosbuvir and ruzasvir support a differentiated, potentially best-in-class profile, combining high efficacy, short treatment duration with low risk of drug-drug interactions, and dosing convenience. By simplifying HCV treatment for both patients and providers, our regimen preferentially aligns with the expanding ‘test-and-treat’ model of care, which we believe will result in more patients treated and an opportunity to accelerate HCV elimination efforts.”
“In parallel, our HEV program underscores our continued commitment to developing antiviral therapeutics for serious viral diseases where significant unmet needs persist. HEV represents a critical gap in care with no approved therapies, leaving vulnerable populations including transplant recipients and other immunocompromised patients at risk for rapid disease progression. Following encouraging preclinical data, we look forward to advancing our potential first-in-class candidate, AT-587, into the clinic mid-year,” Dr. Sommadossi added.
Approaching Pivotal Milestones in Phase 3 Program for Potential Best-in-Class HCV Regimen
Atea continues to advance its global Phase 3 program for the treatment of chronic HCV infection. In the Phase 3 program, Atea is comparing the fixed-dose combination (FDC) regimen of bemnifosbuvir (BEM), a nucleotide analog polymerase inhibitor, and ruzasvir (RZR), an NS5A inhibitor, to the FDC regimen of sofosbuvir and velpatasvir. The regimen of BEM/RZR is administered orally once-daily for eight weeks (in patients without cirrhosis) or 12 weeks (in patients with compensated cirrhosis) while the regimen of sofosbuvir and velpatasvir is administered orally once-daily for 12 weeks to all patients, regardless of cirrhosis status.
The global Phase 3 program consists of two open-label, controlled trials:
- C-BEYOND (conducted in North America): Enrollment completed in December 2025 with more than 880 patients; topline results expected mid-2026.
- C-FORWARD (conducted outside North America): Enrollment on track for completion mid-2026; topline results expected around year-end 2026.
The primary endpoint for each trial is HCV RNA < lower limit of quantitation (LLOQ) at 24 weeks from the start of treatment and encompasses sustained virologic response 12 weeks post-treatment (SVR12) in each arm. Measurement at 24 weeks from the start of treatment is to ensure the primary endpoint measurement occurs at the same relative timepoint from the start of treatment in all patients. The primary endpoint will be assessed in the modified intent-to-treat population in C-BEYOND and in the per-protocol population in C-FORWARD.
Results Support a Differentiated and Competitive Profile for the Treatment of HCV
Results from Atea’s Phase 2 clinical study, together with results from other preclinical and clinical studies, continue to support a differentiated profile for BEM/RZR. In the Phase 2 study, the 8-week regimen achieved
Last year, Atea presented data supporting a potentially differentiated antiviral mechanism of action. BEM has an established mechanism of inhibition of HCV RNA leading to chain termination, blocking viral production and replication inside the host cell. However, modeling of HCV viral kinetics from a Phase 1b study suggests that BEM may also inhibit the assembly/secretion of new HCV virions into the bloodstream. These data may further explain the high antiviral potency of BEM/RZR.
Atea believes that collectively, these product attributes and study results position BEM/RZR competitively within the evolving HCV landscape. This is particularly relevant as the ‘test-and-treat’ model of care, which enables rapid diagnosis and treatment initiation at the point of care, is increasingly adopted by healthcare providers and supported by stakeholders as critical to HCV elimination efforts. HCV remains a significant global healthcare burden, affecting as many as four million people in the United States (US), according to the CDC.
Preclinical Results Presented at the Conference on Retroviruses and Opportunistic Infections (CROI) 2026 Support AT-587 as a Potential First-in-Class Therapy for HEV
In 2025, Atea strategically expanded its pipeline to target hepatitis E virus (HEV), for which no approved therapies currently exist. If successful, the HEV program could address a substantial unmet medical need for immunocompromised patients and other high-risk populations, such as transplant recipients, for whom HEV is a serious disease that can rapidly progress to cirrhosis.
At CROI 2026, Atea presented in vitro data showing that two drug candidates, AT-587 and AT-2490, were potent inhibitors of HEV replication. The compounds were reported to be 30- to 150-fold more potent against HEV than either sofosbuvir or ribavirin, active against all flaviviruses tested as well as rubella and chikungunya, and associated with high levels of active metabolite formation in human liver cells. Neither compound showed toxicity in the reported studies. Atea selected AT-587 as the lead product candidate and anticipates initiating a Phase 1 clinical program for AT-587 in mid-2026.
First Quarter 2026 Financial Results
Cash, Cash Equivalents and Marketable Securities:
Research and Development Expenses: Research and development expenses increased by
General and Administrative Expenses: General and administrative expenses decreased by
Interest Income and Other, Net: Interest income and other, net, decreased by
Income Taxes: Income tax expense was
| Condensed Consolidated Statement of Operations and Comprehensive Loss (in thousands, except share and per share amounts) (unaudited) | ||||||||
| Three Months Ended March 31, | ||||||||
| 2026 | 2025 | |||||||
| Operating expenses | ||||||||
| Research and development | $ | 41,134 | $ | 29,584 | ||||
| General and administrative | 6,874 | 9,457 | ||||||
| Total operating expenses | 48,008 | 39,041 | ||||||
| Loss from operations | (48,008 | ) | (39,041 | ) | ||||
| Interest income and other, net | 2,618 | 4,972 | ||||||
| Loss before income taxes | (45,390 | ) | (34,069 | ) | ||||
| Income tax expense | (50 | ) | (203 | ) | ||||
| Net loss | $ | (45,440 | ) | $ | (34,272 | ) | ||
| Other comprehensive loss | ||||||||
| Unrealized loss on available-for-sale investments | (271 | ) | (115 | ) | ||||
| Comprehensive loss | $ | (45,711 | ) | $ | (34,387 | ) | ||
| Net loss per share - basic and diluted | $ | (0.57 | ) | $ | (0.40 | ) | ||
| Weighted-average number of common shares - basic and diluted | 79,198,204 | 85,159,254 | ||||||
| Selected Condensed Consolidated Balance Sheet Data (in thousands) (unaudited) | ||||||||
| March 31, 2026 | December 31, 2025 | |||||||
| Cash, cash equivalents and marketable securities | $ | 256,006 | $ | 301,830 | ||||
| Working capital(1) | 229,830 | 271,207 | ||||||
| Total assets | 267,076 | 315,218 | ||||||
| Total liabilities | 33,367 | 39,784 | ||||||
| Total stockholder's equity | 233,709 | 275,434 | ||||||
| (1) | Atea defines working capital as current assets less current liabilities. See the Company’s condensed consolidated financial statements in its Quarterly Report on Form 10-Q for the three months ended March 31, 2026 for further detail regarding its current assets and liabilities. | |
Conference Call and Webcast
Atea will host a conference call and live audio webcast to discuss first quarter 2026 financial results and provide a business update today at 4:30 p.m. ET. To access the live conference call, participants may register here. The live audio webcast of the call will be available under "Events and Presentations" in the Investor Relations section of the Atea website at ir.ateapharma.com. To participate via telephone, please dial 1-877-407-0779 (U.S.) or 1-201-389-0914 (International) and use conference ID number 13759581. An archive of the audio webcast will be available on Atea’s website approximately two hours after the conference call and will remain available for at least 90 days following the event.
About Bemnifosbuvir and Ruzasvir for HCV
BEM has been shown in in vitro studies to be approximately 10-fold more active than sofosbuvir (SOF) against a panel of laboratory strains and clinical isolates of HCV GT 1–5. In vitro studies have also demonstrated BEM remained fully active against SOF resistance-associated substitutions (S282T), with up to 58-fold more potency than SOF. The pharmacokinetic (PK) profile of BEM supports once-daily dosing for the treatment of HCV. BEM has been shown to have a low risk for drug-drug interactions. BEM has been administered to over 3,000 subjects and has been well-tolerated at doses up to 550 mg for durations up to 12 weeks in healthy subjects and patients.
RZR has demonstrated highly potent and pan-genotypic antiviral activity in preclinical (picomolar range) and clinical studies. RZR has been administered to over 2,800 HCV-infected patients at daily doses of up to 180 mg for 12 weeks and has demonstrated a favorable safety profile. The PK profile of RZR supports once-daily dosing.
About HCV
HCV is a blood-borne, positive-sense, single-stranded RNA (ssRNA) virus that primarily infects liver cells. HCV is a leading cause of chronic liver disease and liver transplants, spreading via blood transfusion, hemodialysis and needle sticks, with approximately 240,000 deaths occurring each year. Despite the availability of DAAs, HCV continues to be a significant global healthcare issue. An estimated 50 million people worldwide are chronically infected with HCV and there are approximately one million new infections each year. In the US, as many as four million people are estimated to have HCV with annual new infections outpacing treatment rates. HCV infections in the US predominate in patients in the age group between 20 and 49 years old, and it is estimated that less than
About HEV
HEV is a positive sense, ssRNA virus which infects the liver and remains an under-recognized global health challenge with an estimated 20 million infections annually. Waterborne transmission of HEV genotypes 1 and 2 causes mostly acute self-limiting hepatitis in developing regions, whereas foodborne transmission of HEV genotype 3 predominates in the US and Europe and causes chronic hepatitis in immunocompromised patients, which can lead to cirrhosis in three to five years. There is a growing number of immunocompromised patients, a population that includes solid organ transplant and hematopoietic stem cell transplant recipients and patients with hematologic malignancies such as multiple myeloma. Each year, in the US and Europe,
About Atea Pharmaceuticals
Atea is a late-stage clinical biopharmaceutical company focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. Leveraging Atea’s deep understanding of antiviral drug development, nucleos(t)ide chemistry, biology, biochemistry and virology, Atea has built a proprietary nucleos(t)ide prodrug platform to develop novel product candidates to treat ssRNA, viruses, which are a prevalent cause of serious viral diseases. Atea plans to continue to build its pipeline of antiviral product candidates by augmenting its nucleos(t)ide platform with other classes of antivirals that may be used in combination with its nucleos(t)ide product candidates. Atea’s Phase 3 program is evaluating the FDC regimen of BEM, a nucleotide analog polymerase inhibitor, and RZR, an NS5A inhibitor, to treat HCV. Atea anticipates initiating clinical development of AT-587, a nucleotide analog, for the treatment of HEV in mid-2026. For more information, please visit www.ateapharma.com.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include but are not limited to statements regarding the potential best-in-class profile of the BEM/RZR regimen for the treatment of HCV, the potential opportunity to advance efforts to eradicate HCV, the potential to develop a product for the treatment of HEV, anticipated milestone events and timelines for clinical trials including the timeline for readout of the HCV Phase 3 clinical trials results and initiation of the HEV clinical development, future results of operations and business strategy. When used herein, words including “expected,” “should,” “anticipated,” “believe,” “will,” “plans”, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Atea’s current expectations and various assumptions. Atea believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Atea may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, uncertainties inherent in the drug discovery and development process and the regulatory submission or approval process, unexpected or unfavorable safety or efficacy data or results observed during clinical trials or in data readouts; delays in or disruptions to clinical trials or our business; our reliance on third parties over which we may not always have full control; our ability to manufacture sufficient commercial product; competition from approved treatments for HCV; dependence on the success of Atea’s most advanced product candidates, in particular the BEM/RZR regimen for the treatment of HCV; as well as the other important factors discussed under the caption “Risk Factors” in Atea’s Annual Report on Form 10-K for the year ended December 31, 2025 as such factors may be updated from time to time in its other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. All forward-looking statements represent management’s estimates as of the date of this press release. While Atea may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. Forward-looking statements should not be relied upon as representing Atea’s views as of any date subsequent to the date of this press release.
Contacts
Jonae Barnes
SVP, Investor Relations and Corporate Communications
617-818-2985
barnes.jonae@ateapharma.com
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
